Kalohexis Appoints Garry Menzel, Ph.D., to Board of Directors

Dr. Menzel brings over 30 years of global healthcare executive leadership with broad experience in building successful companies

NORTHBROOK, Ill., Sept. 1, 2026 /PRNewswire/ -- Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced the appointment of Garry Menzel, Ph.D., to its Board of Directors.

"Garry is a seasoned global healthcare executive with a very strong track record in advising and leading successful life sciences companies," said Russell Potterfield, Chief Executive Officer of Kalohexis. "He has used those skills in many situations that are relevant for Kalohexis and proven himself adept at integrating effectively with different teams to produce lifesaving therapies. I look forward to working with him as we advance our differentiated melanocortin-based approach to restoring metabolic balance."

Dr. Menzel is a senior global healthcare executive and investor with a diverse background in science, strategy, finance and operations. He currently serves as an Operating Partner at Global Healthcare Opportunities (GHO) Capital, Europe's leading healthcare specialist private equity firm. Previously, he was the President and Chief Executive Officer of oncology company TCR² Therapeutics, which he led from concept to clinical success while raising more than $500 million before its strategic merger with Adaptimmune in 2023. He also co-founded Black Diamond Therapeutics, a Fierce 15-winning clinical-stage precision oncology company and continues to serve on its Board of Directors where he is Chair of the Audit Committee. Prior executive leadership roles included serving as Chief Financial Officer of Fortune 500 company DaVita HealthCare Partners and as Chief Operating Officer of Regulus Therapeutics, which was sold to Novartis for $1.7 billion. Recently, he served on the Board of genetic disease company Stoke Therapeutics.

Dr. Menzel began his life sciences career in an advisory role, first as a strategy consultant with Bain then as an investment banker with Goldman Sachs and Credit Suisse where he led their global biotechnology franchises. During his investment banking tenure, Dr. Menzel worked on more than $100 billion in transactions, including many that were transformative for the industry. These ranged from IPOs to M&A.

"Kalohexis has the opportunity to transform the treatment of obesity with 710GO by enabling healthier, more durable weight loss in general obesity without the limitations seen with incretins, such as loss of lean muscle mass and weight rebound following treatment cessation," said Dr. Menzel. "I am passionate about developing novel therapies and look forward to working with Kalohexis as the team advances its melanocortin-based pipeline, which also includes mifomelatide for cancer cachexia, where there are currently no FDA-approved treatment options."

Dr. Menzel received his Ph.D. in Biochemistry and Molecular Biology from St. John's College, University of Cambridge, his M.B.A. from the Stanford University Graduate School of Business, and his B.Sc. with Honors in Biochemistry from Imperial College of Science & Technology, London.

About Kalohexis, Inc. 
Kalohexis, Inc. is a clinical-stage biotechnology company, spun out of Endevica Bio in March 2026, shaping the next era of metabolic disease care by harnessing the melanocortin system, the body's natural regulator of metabolic homeostasis, to help people live healthier lives. Kalohexis' therapeutic peptide candidates are designed to safely and effectively drug central melanocortin-3 and -4 receptors (MC3R/MC4R) to treat many metabolic disorders. Kalohexis' lead pipeline programs are 710GO, an oral dual MC3R/MC4R agonist to induce healthier, more durable weight loss in general obesity, and mifomelatide, a dual MC3R/MC4R antagonist to treat cachexia in patients with advanced cancers. For more information, visit www.kalohexis.com or follow us on LinkedIn and X. 

Investor and Media Contact:
Argot Partners
[email protected]

SOURCE Kalohexis